NEC and Transgene Announce a Collaboration in the Field of Individualized Cancer Immunotherapy, Leveraging NEC's AI and Transgene's myvac Platform
TOKYO, Oct, 30 2018 - (JCN Newswire) - NEC Corporation (TSE: 6701) and Transgene today announced the signing of a Memorandum of Understanding (MOU) for a strategic collaboration aimed at the treatment of solid cancers. The companies will cooperate in clinically assessing the predictive capabilities of NEC's artificial intelligence (AI) and the therapeutic potential of Transgene's myvac(1) MVA-based viral vector platform in an individualized immunotherapy for the treatment of solid cancers. The experimental products from this collaboration are expected to enter clinical trials in 2019.
NEC and Transgene will co-invest in the first stage of development of an individualized immunotherapy, which includes clinical trials focusing on ovarian cancer and HPV-negative head and neck cancer.
Immunotherapy is rapidly becoming the treatment of choice to fight cancer as it activates the patient's own immune system to attack cancer cells.
NEC and Transgene have capitalized on the recent progress in AI and advances in genome sequencing to create individualized immunotherapy, which is adapted to the unique characteristics of each patient's mutational landscape as well as their predicted immune responses. The product is based on a viral vector (MVA) developed by Transgene with a proven clinical safety track record and is known for its efficient immunogenicity and anti-tumor efficacy in patients.
The viral vector will be used to target neoantigens identified using NEC's proprietary algorithm. NEC has been developing solutions in the drug discovery field for close to two decades. NEC's neoantigen prediction system(2) was developed and validated based on publicly available databases, as well as internal wet lab datasets, some of which were already used to identify clinically relevant antigens in other oncology indications.
These planned clinical trials leverage the world-leading expertise and technologies of a network of companies and research centers, including:
NEC's cutting-edge AI technology, "NEC the WISE"(3), for identifying and prioritizing patient-specific neoantigens, and Transgene's unrivaled MVA-based, viral vector technology and the myvac platform.
"The emerging personalized medicine field holds great potential for the application of NEC's core technology, and we are pleased to be working with Transgene with the goal of developing state-of-the-art personalized immunotherapies," said Motoo Nishihara, Senior Vice President, Head of NEC Laboratories.
"Engaging the body's own immune system in the fight against cancer has shown great promise and sparked unprecedented interest among oncology drug makers. This makes it imperative for NEC to become part of the immunotherapy race as soon as possible," said Osamu Fujikawa, Senior Vice President, Business Innovation Unit, NEC Corporation.
"This collaboration brings together artificial intelligence and our expertise in viral vector engineering to enable the development of a truly innovative treatment based on the myvac platform. We believe that our collaboration with NEC will allow us to provide an efficacious and robust therapy for the many patients who have solid tumors and could benefit from this cutting-edge individualized approach, and to successfully advance the development of the myvac platform to the market" said Eric Quemeneur, Pharm.D., Ph.D., Executive VP, Chief Scientific Officer of Transgene.
myvac is a viral vector (MVA) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. The myvac-derived products are designed to stimulate the patient's immune system, recognize and destroy tumors using the patient's own cancer specific genetic mutations. Transgene has set up an innovative network that combines bioengineering, digital transformation, established vectorization know-how and unique manufacturing capabilities.
(2) NEC's Neoantigen Prediction System
NEC's neoantigen prediction utilizes its proprietary AI, such as graph-based relational learning, which is combined with other sources of data to discover candidate neoantigen targets. NEC comprehensively evaluates the candidate neoantigens with a primary focus placed on its in-house MHC-binding affinity prediction. These allow NEC to effectively prioritize the numerous candidate neoantigens identified in a single patient.
(3) NEC the WISE
NEC the WISE is a term for the Company's cutting-edge portfolio of AI technologies.
NEC announces new AI technology brand, "NEC the WISE"
NEC's AI Research:
About NEC Corporation
NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security efficiency and fairness of society. Under the company's corporate message of "Orchestrating a brighter world," NEC aims to help solve a wide range of challenging issues and to create new social value for the changing world of tomorrow. For more information, visit NEC at https://www.nec.com.
Source: NEC Corporation
Sectors: Enterprise IT, BioTech
Copyright ©2018 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
|(from left: Eric Quemeneur, Pharm.D., Ph.D., Executive VP, Chief Scientific Officer, Transgene; Kaidre Bendjama, Transgene; Motoo Nishihara, Senior Vice President, Head of NEC Laboratories; Osamu Fujikawa, Senior Vice President, Business Innovation Unit, NEC Corporation)|
Latest Press Release
More Latest Release >>
Mitsubishi Corporation has Reached Agreement to Sell its Interests in the Clermont and Ulan Coal Mines in Australia
Dec 18, 2018 18:49 JST
Sharp to Take Part in CES 2019, First Time in 4 Years
Dec 18, 2018 18:37 JST
Toyota 5 Continents Drive Project Following Africa, the Project Moves to its Final Continent--Asia--in 2019 and 2020
Dec 18, 2018 18:05 JST
Eisai: Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3's RNA Splicing Platform
Dec 18, 2018 11:38 JST
Hitachi to Strengthen Energy Solutions Business with the Acquisition of ABB's Power Grids Business
Dec 18, 2018 08:25 JST
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Brazil with Eurofarma
Dec 17, 2018 09:21 JST
NEC Takes Top Spot as Worldwide Market Leader in MZA's Global Call Control (PBX-IP PBX) Market Report
Dec 14, 2018 15:40 JST
"docomo Money Transfer" Mobile Remittance Service to Add China and Thailand
Dec 14, 2018 14:34 JST
Hitachi to Transfer Shares in Hitachi Procurement Service to Infosys, Panasonic, and PASONA
Dec 14, 2018 14:10 JST
Mitsubishi Corporation to Participate in Carbon Fiber Reprocessing Business in the UK
Dec 14, 2018 12:53 JST
Mitsubishi Shipbuilding Holds Christening Ceremony for LPG Carrier "LAUREL PRIME"
Dec 14, 2018 11:13 JST
NSITEXE Develops Test Chip with Next-generation Semiconductor IP Core Called a DFP
Dec 13, 2018 18:33 JST
NEC: Members Selected for the Research Program for the Development of a Quantum Annealing Machine Enabling High-Efficiency, High-Speed Processing
Dec 13, 2018 17:37 JST
Mitsubishi Motors to Relocate to a New Headquarters
Dec 13, 2018 17:20 JST
Production Milestone for Pratt & Whitney GTF PW1200G Engine at Mitsubishi Heavy Industries Aero Engines in Japan
Dec 13, 2018 10:28 JST
Mitsubishi Motors Secures Largest Fleet Sale of XPANDER to Garuda Indonesia
Dec 12, 2018 14:04 JST
Mitsubishi Corporation: Smart Meter Data Collection System 'Experiment' Launched in Hamamatsu
Dec 12, 2018 13:20 JST
GARDP, Eisai and Takeda Announce Partnership in the Search for New Antibiotics
Dec 12, 2018 10:06 JST
Showa Denko Announces Notice Regarding the Repurchase of Own Shares
Dec 11, 2018 14:00 JST
Showa Denko Forecasts Payment of Term-end Dividend
Dec 11, 2018 14:00 JST